Home / Market News / $VRDN
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Wedbush Adjusts Price Target on Viridian Therapeutics

Nov 9, 2026, 11:11 PM UTC · Primary ticker $VRDN

Wedbush Securities has increased its price target for Viridian Therapeutics (VRDN) from $42 to $44, while reiterating an Outperform rating. This adjustment reflects the analyst's updated assessment of the company's clinical advancements and market standing, suggesting a positive, albeit moderate, re-evaluation of its future prospects.

Wedbush Securities adjusted its price target for Viridian Therapeutics (VRDN) from $42 to $44, while maintaining an Outperform rating. This change is a direct result of the analyst's updated outlook on the company's clinical progress, indicating a more favorable view of its pipeline and market potential. For VRDN, this is a positive signal, potentially boosting investor confidence and providing a short-term upward nudge to the stock price. The long-term implications depend on whether the clinical updates continue to validate Wedbush's optimistic outlook. Traders might see this as an opportunity for a modest upside, though the impact is not as significant as a major clinical trial readout or M&A.

$VRDN positive Price target increase and maintained Outperform rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.